Shionogi Of Japan Working To Become Multinational
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi has ambitious plans to transform itself into a multinational company in the pharmaceutical industry. It has five drugs in middle- to late-stage clinical trials in its three areas of concentration - infectious diseases and metabolic and pain syndromes. A new Shionogi administration took over the company April 1 and set goals for itself through its 2009 fiscal year. In the past the company has relied on ties to other multinationals for most of its earnings, but patents on most of those drugs are due to expire within the next 10 years. Already in the current fiscal year, Shionogi has seen its U.S. sales out-number sales in its home country. (Click here for more - a subscription may be required
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.